The U.S. Food and Drug Administration (FDA) has officially finalized its long-awaited guidance regarding formal meetings between the agency and sponsors of drug and biological product applications. This regulatory update, rooted in the Prescription Drug User Fee Act (PDUFA), represents a significant evolution in how pharmaceutical companies interact with the agency during the development and review lifecycle. By formalizing meeting categories and refining the conditions under which written responses replace interactive sessions, the FDA is attempting to streamline its operations while navigating the growing tension between administrative efficiency and the industry’s desire for real-time collaboration.
The Evolution of Regulatory Communication: A Chronology
The path to this final guidance has been marked by a multi-year effort to modernize the agency’s engagement strategy. The journey began in earnest with the December 2017 guidance, which served as the baseline for formal meetings for years. However, as the complexity of drug development accelerated—driven by breakthroughs in gene therapy, precision medicine, and novel biologics—the 2017 framework began to show its limitations.
On September 22, 2023, the FDA released a comprehensive draft guidance intended to replace the 2017 version. This draft was transformative, introducing two new meeting categories: Type D and INTERACT (Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products). The draft invited a flurry of public comments, most notably from the Biotechnology Innovation Organization (BIO), which sought to clarify the boundaries of these new pathways. Following this period of industry feedback, the agency spent months deliberating on the structural nuances of these interactions, culminating in the final guidance released in mid-2025.
Understanding the New Meeting Taxonomy
The finalized guidance solidifies the agency’s meeting hierarchy, providing clearer definitions for each classification. While Type A, B, and C meetings remain foundational, the solidification of Type D and INTERACT meetings marks a major shift in how the FDA handles early-stage and narrow-scope inquiries.
The INTERACT Meeting: Niche and Specific
Perhaps the most scrutinized change involves the INTERACT meeting. In the 2023 draft, these meetings were positioned as a catch-all for early development challenges. The final guidance, however, imposes stricter guardrails. The FDA has clarified that INTERACT meetings are explicitly not appropriate for sponsors who have already held a pre-IND (Investigational New Drug) meeting or have already filed an IND. This correction directly addresses concerns raised by industry stakeholders, including BIO, who argued that without a clear distinction between pre-IND and INTERACT meetings, the system would become redundant and confusing for developers.
Type D Meetings: Refined Scenarios
Type D meetings, which typically address a narrow range of topics or a single specific issue, remain a vital tool for sponsors needing rapid, focused feedback. To improve clarity, the final guidance adds three new, specific scenarios to the criteria for requesting a Type D meeting. This expansion aims to minimize the "trial and error" process sponsors often face when determining whether a question warrants a full meeting or a simple correspondence.
Reclassifying Type B and C Interactions
The final guidance also updates the scope of traditional meeting types:
- Type B: Now formally includes pre-sNDA (Supplemental New Drug Application) and pre-sBLA (Supplemental Biologics License Application) meetings.
- Type C: Now includes provisions for seeking FDA feedback on the content of representative labeling for nonprescription drugs.
The "Written Response Only" (WRO) Controversy
Perhaps the most contentious aspect of the new guidance is the formalization of the "Written Response Only" (WRO) policy. The FDA has asserted that it may grant a WRO instead of a live meeting for B, C, D, and INTERACT meetings, regardless of what the requester initially sought.
For industry sponsors, this is a point of significant friction. In its response to the draft guidance, BIO noted that the increasing prevalence of WROs—even for complex, high-stakes topics—often leaves sponsors without the necessary nuance required to advance a program. When a written response is vague or misses the intent of the sponsor’s query, the lack of an immediate, interactive forum prevents the collaborative problem-solving that is often essential for regulatory success.
Despite industry pleas for the FDA to publish explicit criteria for when a WRO is deemed sufficient, the final guidance remains silent on this, leaving the decision largely to the discretion of the review division.
Operational Requirements: Documentation and Submission
The final guidance also introduces stricter requirements for submitting meeting requests. In a reversal of the 2023 draft, the FDA has restored a requirement from the 2017 guidance: sponsors must now include a specific list of objectives or desired outcomes when requesting a meeting. This requirement forces sponsors to articulate the "why" behind their request, rather than simply listing questions.
Furthermore, the agency has implemented a "10-question cap" for meeting packages. To prevent "question stuffing," where sponsors embed multiple queries under a single heading, the FDA has mandated a strict numbering convention: sub-questions must be numbered individually. For Type D and INTERACT meetings, the meeting package is now required at the time of the request, mirroring the rigor previously reserved for Type A and certain Type C meetings.
Implications for the Pharmaceutical Industry
The finalization of this guidance has profound implications for how biopharmaceutical companies budget for and execute their regulatory strategies.
The Impact on Small-to-Midsize Biotech
For smaller firms with limited internal regulatory resources, the new meeting hierarchy provides a more granular way to approach the FDA. However, the requirement for complete meeting packages at the time of request for Type D and INTERACT meetings means that these companies must be "investment-ready" in their documentation much earlier in the process.
The Shift Toward "Regulatory Agility"
Large pharmaceutical companies must now adapt their internal processes to accommodate the WRO-first reality. Regulatory affairs departments are increasingly being tasked with drafting more robust, clear, and comprehensive initial meeting questions, knowing that they may not get a second chance to clarify those questions in a live teleconference.
A Narrowing Scope of Utility
It is crucial to note that these guidelines do not apply to Abbreviated New Drug Applications (ANDAs), biosimilar applications, or medical devices. Companies operating in these sectors will continue to follow their existing, separate regulatory pathways, which may lead to a growing divergence in the regulatory experience between innovator drug developers and those in the generic or biosimilar spaces.
Conclusion: A Balancing Act
The FDA’s finalized PDUFA meeting guidance is a pragmatic, if imperfect, solution to the challenges of modern drug development. By creating a more formal structure for early-stage and focused interactions, the agency is providing much-needed clarity for sponsors. However, the continued reliance on Written Responses—and the refusal to provide transparent criteria for their use—suggests that the tension between the agency’s need for efficiency and the industry’s need for interactive dialogue remains unresolved.
As the industry begins to operate under these new rules, the long-term success of this policy will depend on the consistency of the FDA’s review divisions. If the guidance is applied with flexibility and a genuine commitment to addressing the complexities of drug development, it could usher in a new era of efficient regulatory interaction. If, however, it becomes a tool for further insulating the agency from the sponsors it regulates, the industry may find that the "modernization" of meetings has come at the cost of the very collaboration necessary to bring life-saving therapies to patients.
Stakeholders are encouraged to monitor how individual review divisions interpret the "appropriateness" of WROs in the coming months, as this will likely be the primary indicator of how these guidelines impact the drug development landscape.
About the Author
